Actualités

Oscar Health reported second-quarter 2026 results showing a shift from a prior-year loss to net income of US$361.81 million and lifted its full-year 2026 guidance to total revenue of US$18.70–US$19.00 billion and earnings from operations of US$500–US$700 million. This combination of a profit turnaround and a sizeable upgrade to operating earnings expectations suggests Oscar’s underlying operations are running more efficiently than previously anticipated. We’ll now examine how Oscar’s...

The biotech company reported record second-quarter revenue fueled by strong sales of its cancer therapy Amtagvi.

Chevron (CVX) has moved into the spotlight after reporting its highest quarterly earnings in six years, with profits tied to Middle Eastern supply disruptions and fresh criticism over windfall gains and elevated fuel prices. See our latest analysis for Chevron. Chevron’s share price has eased in the very short term, with a 1-day share price return of 2.10% and a 7-day share price return of 2.84%. Recent momentum remains positive given a 30-day share price return of 10.89%, a year to date...

JEPI's fat monthly yield has made it a retiree favorite, but a smaller rival running a completely different options playbook has quietly compounded far more wealth over the same period without sacrificing the monthly income routine investors depend on.

Aeva stock is speculative -- but investors are speculating hard after last night's earnings beat.

These two stocks give investors a way to profit from strong industry tailwinds for nuclear energy in the coming decades.

KDP's Q2 earnings and sales beat estimates as JDE Peet's acquisition, U.S. Refreshment Beverages growth and efficiency initiatives lift performance.

Restaurant Brands International (TSX:QSR, NYSE:QSR) reported second quarter 2026 adjusted earnings above Wall Street expectations on Thursday, supported by stronger comparable sales led by Burger King in the US. The company posted adjusted diluted earnings of $1.07 per share, above the $1.03...

IPG (IPGP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Advantest (ATEYY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ford Motor (F) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Does RTX (RTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

IonQ Scores Major U.S. Defense Wins, Stock Jumps

One company builds the hardware that powers AI data centers while the other monetizes the apps that run on them.

ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.

Quanta pairs surging earnings, record backlog and stronger cash flow with a rich valuation. Can growth continue fast enough to justify the premium?

Magna's Q2 earnings beat estimates as Power & Vision margin expansion and productivity gains supported higher profit and raised 2026 guidance.

GTX's Q2 earnings and sales beat estimates on broad-based growth. Margin gains and productivity drove a raised 2026 outlook.

McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.

Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.

Quanta falls 11.7% despite record backlog, stronger earnings and a higher 2026 outlook. Can operating momentum outweigh valuation and execution risks?

Booking offers stability and cash flow, while Axon Enterprise brings one of the most consistent growth records in the market today.

By Jarrett Banks Corpay (NYSE: CPAY) delivered another strong quarter of double-digit organic revenue growth. But increasingly, investors are keyed into management’s capital allocation strategy as a top reason to own the stock. Several analyst notes pointed out that Corpay is evolving into one of the payments industry’s premier capital compounders. JPMorgan said investors should […] The post Corpay’s Price Target Raised by Brokers After Earnings Beat appeared first on ExecEdge.

MercadoLibre's ecosystem gains momentum as marketplace and fintech users deepen engagement, driving higher activity across commerce and financial services.

NYT's Q2 earnings beat estimates as digital subscriptions, higher ARPU and rising digital ads fueled revenue growth.

CPAY's Q2 earnings and revenues beat estimates as Corporate Payments surge, margins expand and the 2026 profit guidance increases.

Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.

MUR's Q2 earnings beat estimates as stronger oil prices, broad production and lower operating costs lift revenues and cash flow.

BorgWarner beats Q2 earnings estimates as cost controls lift margins. It raises 2026 EPS guidance and expands buyback capacity.